Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

October 14, 2015

Warfarin and other vitamin-K antagonists are highly effective when patients blood clotting value is maintained within the narrow therapeutic INR range of 2.0-3.0 as in a clinical trial setting. However in clinical practice - due to the well-known limitations with warfarin - only 51% of diagnosed patients with AF and at risk of stroke receive warfarin7 and fewer than half of these are controlled within the narrow therapeutic range.

Potent antithrombotic effects are achieved with direct thrombin inhibitors by specifically blocking the activity of thrombin (both free and clot-bound), the central enzyme in the process responsible for clot (thrombus) formation. In contrast to vitamin-K antagonists, which variably act via different coagulation factors, dabigatran etexilate provides effective, predictable and consistent anticoagulation with a low potential for drug-drug interactions and no drug-food interactions, without the need for routine coagulation monitoring or dose adjustment.

???With the robust results from RE-LY? dabigatran etexilate, a compound from our own research and development, can revolutionize anticoagulant treatment for physicians and patients,??? commented Dr Andreas Barner, the chairman of the Board of Managing Directors of Boehringer Ingelheim. ???We look forward to expeditiously submitting these results to regulatory authorities around the world so that new options can be made available for millions of patients with atrial fibrillation at risk of stroke.???